To date, several PLK4 inhibitors, including CFI‐400945, Centrinone, Centrinone B, YLT‐11, and YLZ‐F5, have been characterized in cancer cell lines and in vivo xenograft models (Table 1) (Lei et al. 2018; Mason et al. 2014; Wong et al. 2015; Zhu et al. 2020). This evidence concerns the gene PLK4 and cancer.